Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A
Latest Information Update: 20 Nov 2025
At a glance
- Drugs Efanesoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms SYNOVIIIUS
- Sponsors Sanofi
Most Recent Events
- 30 Oct 2025 Planned End Date changed from 15 Jun 2027 to 25 Oct 2027.
- 30 Oct 2025 Planned primary completion date changed from 16 Mar 2027 to 25 Oct 2027.
- 30 Oct 2025 Status changed from not yet recruiting to recruiting.